USA - NASDAQ:BGM - KYG7307E1237 - Common Stock
We assign a fundamental rating of 2 out of 10 to BGM. BGM was compared to 191 industry peers in the Pharmaceuticals industry. BGM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. BGM has a expensive valuation and it also scores bad on growth.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -1.31% | ||
ROE | -1.49% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.41% |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Altman-Z | 36.97 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 1.82 | ||
Quick Ratio | 1.45 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
9.4
-0.12 (-1.26%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 56.88 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 8.39 | ||
P/tB | 36.11 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -1.31% | ||
ROE | -1.49% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | 19.41% | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.01 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 151.04% | ||
Cap/Sales | 6.33% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 1.82 | ||
Quick Ratio | 1.45 | ||
Altman-Z | 36.97 |